| abstract |
A new use of darusentan is provided in preparation of a pharmaceutical composition, for adjunctive administration with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers, to lower blood pressure in a patient having resistant hypertension; wherein the composition is orally deliverable and comprises darusentan in a daily dose effective, in combination with said regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. |